Literatura 2 Tyrosinkinázové inhibitory v léčbě solidních nádorů PharmDr. Šárka Kozáková, MBA Masarykův onkologický ústav, Brno 2 Atezolizumab doc. MUDr. Regina Demlová, Ph.D. Farmakologický ústav LF MU Brno, Oddělení klinických hodnocení MOÚ, Brno MUDr. Renata Hejnová Oddělení klinických hodnocení MOÚ, Brno 2 Novinka v léčbě metastatického kolorektálního karcinomu MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně 3 Bezpečnostní profil ibrutinibu a idelalisibu 3 Podkožní forma rituximabu starý a přesto nový lék: co přináší z pohledu lékaře, zdravotní sestry a pacienta v běžné klinické praxi doc. MUDr. Andrea Janíková, Ph.D. Jana Charouzková Interní hematologická a onkologická klinika FN a LF MU, Brno 3 Interakce léčiv prodlužujících QT interval Mgr. Olga Svobodová Oddělení klinické farmacie Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno PharmDr. Miroslav Turjap, Ph.D. Oddělení klinické farmacie Lékárna, FN Ostrava doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav, LF MU, Brno 3 Fixní kombinace perindopril argininu s amlodipinem prof. MUDr. Jiří Widimský, CSc. Jr. III. interní klinika Centrum pro hypertenzi VFN a 1. LF UK, Praha 4 Inhibice systému RAAS perindoprilem ve vztahu k dysfunkci endotelu: studie PERTINENT 4 Fixní kombinace candesartanu s amlodipinem 4 Intervence kardiovaskulárního rizika, proč vítězíme a selháváme 5 Perindopril erbumin prověřen klinickými studiemi 5 Porovnání klinického efektu Warfarinu PMCS vůči Warfarinu Orion MUDr. Petr Magrot OKB Lab, a. s., Ústí nad Labem Leona Hrdličková, DiS. SVZŠ, Ústí nad Labem 5 Léčba bolesti v těhotenství s ohledem na změnu farmakokinetiky těhotných PharmDr. Eliška Vaculíková Nemocniční lékárna, Pracoviště klinického farmaceuta Nemocnice s poliklinikou Havířov Mgr. Olga Svobodová Oddělení klinické farmacie Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno MUDr. Jan Malaník Gynekologicko-porodní oddělení Slezské nemocnice Opava 6 Tapentadol v léčbě chronické nenádorové bolesti kazuistika MUDr. Lenka Klimešová ARIM, Nemocnice Milosrdných bratří, Brno 6 Nová možnost léčby revmatoidní artritidy Olumiant MUDr. Olga Růžičková Revmatologický ústav, Praha 6 Secukinumab v léčbě pacientky se závažným průběhem psoriázy a psoriatické artritidy kazuistika MUDr. Martina Kojanová, Ph.D. MUDr. Jorga Fialová Dermatovenerologická klinika 1. LF UK a VFN, Praha MUDr. Liliana Šedová Revmatologický ústav, Praha, Revmatologická klinika 1. LF UK, Praha 6 Fixní kombinace azelastinu a fluticason propionátu lékový profil MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha 7 Současný pohled na léčbu idiopatické plicní fibrózy 7 Fosfomycin trometamol od laboratorního ověření účinnosti k urologické praxi MUDr. Miroslav Louda, Ph.D. Urologická klinika FN a LF UK, Hradec Králové MUDr. Miroslav Fajfr, Ph.D. Ústav klinické mikrobiologie, FN Hradec Králové 7 Farmakologická léčba benigní hyperplazie v současnosti MUDr. Jiří Klečka, Ph.D., MBA Urocentrum Plzeň a Urologická klinika FN Královské Vinohrady a 3. LF UK, Praha 7 Význam perorální léčby roztroušené sklerózy v první linii prof. MUDr. Jan Mareš, Ph.D. Neurologická klinika LF UP a FN Olomouc
Tyrosinkinázové inhibitory v léčbě solidních nádorů PharmDr. Šárka Kozáková, MBA Masarykův onkologický ústav, Brno 1 Gunby, R. H. Sala, E. Tartari, C. J., et al.: Oncogenic fusion tyrosine kinases as molecular tagrets for anti-cancer therapy. Anticancer Agents Med Chem, 2007, 77, s. 594 611, doi:10.2174/18715200778411340. 2 Wang, S. C. Hung, M. C.: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res, 2009, 15, s. 6484 6489. 3 Nagaria, N. C. Cogswell, J. Choe, J. K., et al.: Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol, 2005, 23, s. 2423 2424. 4 Bunn, P. A. Kelly, K.: New combination in the treatment of lung cancer. A time for optimism. Chest, 2000, 117, s. 138S 143S. 5 Krákorová, G. Svaton, M.: Afatinib nový ireverzibilní tyrosinkinázový inhibitor v klinické praxi. Remedia, 2014, 24, s. 130 135. 6 Solca, F. Meyer, R.: Inactivation of the EGR signaling pathway by BIBW 2992. A time course analysis. 28-02, 30. 11. 2002. 7 Blažek, J.: Tagrisso (osimertinib, AZD9291). Nové léky 2015/2016. Dostupné z: http://www.noveleky.cz/index.php/onkologie/36-tagrisso- -osimertinib-azd9291, vyhledáno 4. 10. 2017. 8 Petráková, K. Demlová, R.: Lapatinib. Remedia, 2008, 18, s. 13 18. 9 Kadlec, B. Skřičková, J.: Ceritinib v léčbě nemalobuněčného karcinomu plic. Remedia, 2016, 26, s. 29 32. 10 Maillet, D. Martel Lafay, I. Arpin, D., et al.: Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4 ALK rearrangement. J Thorac Oncol, 2013, 8, s. e30 e31. 11 Doebele, R. C. Pilling, A. B. Aisner, D. L., et al.: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res, 2012, 18, s. 1472 1482. 12 Mok, T. Spigel, D. Felip, E., et al.: ASCEND 2: A single arm, open label, multicenter Phase II study of ceritinib in adult patients (pts) with ALK rearranged (ALK+) non small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Abstrakt 8059. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA. 13 Steeghs, N. Nortier, J. W. Gelderblom, H.: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol, 2007, 14, s. 942 953. 14 Carmeliet, P. Jain, R. K.: Angiogenesis in cancer and other diseases. Nature, 2000, 407, s. 249 257. 15 Chow, L. Q. Eckhard, G.: Sunitinib: from rational design to clinical efficacy. J Clin Oncol, 2007, 25, s. 2858 2859. 16 Gibbons, J. J. Discafani, C. Peterson, R.: The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo (abstract 1000). Proc Am Assoc Cancer Res, 1999, 40, s. 301 304. 17 Deeks, E. D. Keating, G. M.: Sunitinib. Drugs, 2006, 66, s. 2255 2266; diskuze s. 2267 2268. 18 Wells, S. A. Gosnell, J. E. Gagel, R. F., et al.: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol, 2010, 28, s. 767 772. 19 Reck, M. Kaiser, R. Mellemgaard, A., et al.; LUME-Lung 1 study group: Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol, 2014, 15, s. 143 155. 20 Wilhelm, S. M. Carter, C. Tang, L., et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64, s. 7099 7109. 21 Choueiri, T. K. Escudier, B. Powles, T., et al.: Cabozantinib versus everolimus in advanced renal cell carcinoma. N Engl J Med, 2015, 373, s. 1814 1823. 22 Rini, B. I. Rixe, O. Bukowski, R. M., et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol, 2005, 23, abstrakt 4509. 23 Vitásková, D. Melichar, B.: Axitinib v léčbě metastatického karcinomu ledviny. Remedia, 2012, 22, s. 442 444. 24 Cabanillas, M. E. Habra, M. A.: Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev, 2016, 42, s. 47 55. 25 Stjepanovic, N. Capdevila, J.: Multikinase inhibitors in the treatment of thyroid cancer. Specific role of lenvatinib. Biologics, 2014, 8, s. 129 139. 26 Gotink, K. J. Verheul, H. M. W.: Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis, 2010, 13, s. 1 14. 27 Obermanová, R., et al.: Regorafenib v léčbě kolorektálního karcinomu. Studie CORRECT a vlastní zkušenosti s léčbou regorafenibem v Masarykově onkologickém ústavu. Remedia, 2014, 24, s. 419 424. Atezolizumab doc. MUDr. Regina Demlová, Ph.D. Farmakologický ústav LF MU Brno, Oddělení klinických hodnocení MOÚ, Brno MUDr. Renata Hejnová Oddělení klinických hodnocení MOÚ, Brno 1 Chen, L.: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 2004, 4, s. 336 347. 2 Taube, J. M.: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesion supports anadaptive resistence mechanism of immunees cape. Sci Transl Med, 2012, 4, 127ra37. 3 Keir, M. E. Butte, M. J. Freemang, J., et al.: PD-1 and its ligands in tolerance and immunity. J Annu Rev Immunol, 2008, 26, s. 677 704. 4 Dong, H. Strome, S. E. Salomao, D. R., et al.: Tumor-associated B7-h1 promotes T-cell apoptosis: a potential mechanism of immuneevasion. Nat Med, 2002, 8, s. 793 800. 5 Curiel, T. J. Wei, S. Dong, H., et al.: Blockade of B7-h1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med, 2003, 9, s. 562 567. 6 Patsoukis, N. Sari, D. Boussiotis, V. A.: PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle, 2012, 11, s. 4305 4309. 7 Patsoukis, N. Bardhan, K. Chatterjee, P., et al.: PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun, 2015, 6, s. 6692. 8 Staron, M. M. Gray, S. M. Marshallh, D., et al.: The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection. Immunity, 2014, 41, s. 802 814. 9 Chinai, J. M. Janakiram, M. Chen, F., et al.: New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci, 2015, 36, s. 587 595. 10 Barlesi, F., et al.: Primary analysis from OAK, a randomized Phase III study comparing atezolizumab with docetaxel in advanced NSCLC. Prezentováno na setkání European Society for Medical Oncology, Kodaň, Dánsko, říjen 2016. 11 Spira, A., et al.: Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs. docetaxel in 2L/3L NSCLC (POPLAR). Prezentováno na setkání American Society of Clinical Oncology, Chicago, USA, květen 2015. 12 Fehrenbacher, L. Spira, A. Ballinger, M., et al.: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 387, s. 1837 1846. 13 Bilek, O. Bohovicova, L. Demlova, R., et al.: Non-small cell lungcancer from immunobiology to immunotherapy. Klin Onkol, 2016, 29, suppl. 4, s. 78 87. 14 Powles, T.: IMvigor 211: A phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. Prezentováno na druhé specializované konferenci European Association for Cancer Research (EACR), American Association for Cancer Research (AACR) a Italian Cancer Society (SIC), Florencie, Itálie, 2017. 15 Rosenberg, J., et al.: Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (muc): Results from a pivotal multicenter phase II study (IMvigor 210). Prezentováno na European Cancer Congress, Vídeň, Rakousko, září 2015. 16 Lakomy, R. Poprach, A.: Side-effects of modern immunotherapy and how to solve them in the clinics. Klin Onkol, 2015, 28, suppl. 4, s. 4S103 114. 17 Demlova, R. Valik, D. Obermannova, R., et al.: The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-check point inhibitors. Physiol Res, 2016, 65, suppl. 4, s. 455 462. 18 www.clinicaltrials.gov Novinka v léčbě metastatického kolorektálního karcinomu MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně 1 Dostupné z: www.svod.cz. 2 National Comprehensive Cancer Network. NCCN guidelines for colon cancer (version 1.2017). 2017. Dostupné z: http://www.nccn.org/ professionals/physician_gls/f_guidelines.asp, vyhledáno 4. 12. 2017. 3 Emura, T. Murakami, Y. Nakagawa, F., et al.: A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med, 2004, 13, s. 545 549. 4 Hong, D. S. Abbruzzese, J. L. Bogaard, K., et al.: Phase I study to determine the safety and pharmacokinetics of oral administrativ of TAS-102 in patients with solid tumors. Cancer, 2006, 107, s. 1383 1390. 5 Overman, M. J. Varadhachary, G. Kopetz, S., et al.: Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs, 2008, 26, s. 445 454. 6 Green, M. C. Pusztai, L. Theriault, L. R., et al.: Phase I study to determine the safety of oral administrativ of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 2006, 24, abstrakt 10576. 7 Doi, T. Ohtsu, A. Yoshino, T., et al.: Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer, 2012, 107, s. 429 434. 8 Yoshino, T. Mizunuma, N. Yamazaki, K., et al.: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol, 2012, 13, s. 993 1001. 9 Mayer, R. J. Van Cutsem, E. Falcone, A., et al.: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med, 2015, 372, s. 1909 1919. 10 Ohtsu, A. Yoshino, T. Falcone, A., et al.: Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. ASCO 2016, abstrakt 3556. 11 Nishina, T. Yoshino, T. Shinozaki, E., et al.: Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030). ASCO 2016, abstract 3557. 12 Dostupné z: www.servier.cz/documents/spc/lonsurf_spc.pdf, vyhledáno 4. 12. 2017 13 Dostupné z: www. olecich.cz 14 Spurná, Z. Brančíková, D. Katolická, J.: Kvalita života pacienta při podávání perorální onkologické léčby. Onkologie, 2009, 3, s. 101 105.
Bezpečnostní profil ibrutinibu a idelalisibu 1 Byrd, et al.: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. ASCO 2017, abstrakt #7510. 2 Puła, A. Stawiski, K. Braun, M., et al.: Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. Leuk Lymphoma, 11. 9. 2017, s. 1 11. 3 Salles, G. Schuster, S. J. de Vos, S., et al.: Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent- -refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica, 2017, 102, s. e156 e159. 4 PRAC concludes review of Zydelig and issues updated recommendations for use. Dostupné z: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002568. jsp&mid=wc0b01ac058004d5c1, vyhledáno 6. 11. 2017. 5 Jin, F. Robeson, M. Zhou, H., et al.: The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Cancer Chemother Pharmacol, 2015, 76, s. 1133 1141. 6 Jin, F. Robeson, M. Zhou, H., et al.: The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol, 2015, 55, s. 944 952. Podkožní forma rituximabu starý a přesto nový lék: co přináší z pohledu lékaře, zdravotní sestry a pacienta v běžné klinické praxi doc. MUDr. Andrea Janíková, Ph.D. Jana Charouzková Interní hematologická a onkologická klinika FN a LF MU, Brno 1 SPC Mabthera EMA 2017. Dostupné z: www.ema.europa.eu. Mabthera-EMEA/H/C/000165-IA/0136. 2 Casulo, C. Maragulia, J. Zelenetz, A. D.: Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for reccurent infections. Clin Lymphoma Myeloma Leuk, 2013, 13, s. 106 111. 3 Ghielmini, M. Vitolo, U. Kimby, E., et al.: ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol, 2013, 24, s. 561 576. 4 Dreyling, M. Thieblemont, C. Gallamini, A., et al.: ESMO Consensus conferences: guidelines on malignant lymphoma, part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol, 2013, 24, s. 857 877. 5 Shpilberg, O. Jackisch, C.: Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. British J Cancer, 2013, 109, s. 1556 1561. 6 Salar, A. Avivi, I. Larouche, J., et al.: Final results of the BP 22333 Study demonstrate noninferior pharmacokinetics and safety of subcutaneous versus intravenous rituximab as maintenance therapy in follicular lymphoma. Hematol Oncol, 2013, 31, suppl. 1, s. 195. 7 Davies, A. Merli, F. Mihaljevic, B., et al.: Pharmakokinetics, safety, and overall response rate achieved with subcutaneous rituximab plus chemotherapy were comparable to those with intravenous administration in the first-line treatment of patients with follicular lymphoma: stage 1 results of the phase 3 SABRINA Study (BO22334). Hematol Oncol, 2013, 31, suppl. 1, abstrakt 194. Interakce léčiv prodlužujících QT interval Mgr. Olga Svobodová Oddělení klinické farmacie Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno PharmDr. Miroslav Turjap, Ph.D. Oddělení klinické farmacie Lékárna, FN Ostrava doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav, LF MU, Brno 1 Goldenberg, I. Zareba, W. Moss, A.: Long QT syndrom. Curr Probl Cardiol, 2008, 11, s. 629 694. 2 Moss, A. Robinson, J.: Clinical features of the idiopathic long QT syndrome. Circulation, 1992, 85, s. 1140 1144. 3 Jasiak, N. Bostwick, J.: Risk of QT/QTc prolongation among newer non-ssri antidepressants. Ann Pharmacother, 2014, 48, s. 1620 1628. 4 Roden, D. George, A.: Structure and functions of cardiac sodium and potassium channels. Am J Physiol, 1997, 273, s. 511 525. 5 Hedly, P. Jorgensen, P. Schlamowitz, S., et al.: The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat, 2009, 30, s. 1486 1511. 6 Yang, P. Kanki, H. Dorlet, B., et al.: Allelic variants in long-qt disease genes in patients with drug-associated torsades de pointes. Circulation, 2002, 105, s. 1943 1948. 7 Eijgelsheim, M. Stricker, B. van Noord, C.: Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol, 2010, 1, s. 16 23. 8 Online dostupné z: https://crediblemeds.org/new-drug-list/, vyhledáno 28. 9. 2017. 9 Roden, D. M.: Pharmacogenetics of potassium channel blockers. Card Electrophysiol Clin, 2016, 8, s. 385 393. 10 Briasoulis, A. Agarwal, V. Pierce, W. J.: QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology, 2011, 120, s. 103 110. 11 Lee, K. Jim, M. Tang, S., et al.: QT prolongation and torsades de pointes associated with clarithromycin. Am J Med, 1998, 4, s. 395 396. 12 Owens, R., jr.: QT prolongation with antimicrobial agents: understanding the significance. Drugs, 2004, 10, s. 1091 1124. 13 Krausová, L. Grim, J. Pávek, P.: Azolová antimykotika: mechanismy lékových interakcí. Klin Farmakol Farm, 2009, 2, s. 86 89. 14 Glassman, A. Bigger, J.: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry, 2001, 11, s. 1774 1782. 15 Veiweg, W.: New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry, 2003, 5, s. 205 215. 16 Casazza, F. Fiorista, F. Rustici, A., et al.: Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case. G Ital Cardiol, 1986, 12, s. 1058 1061. 17 Online dostupné z: http://www.sukl.cz/riziko-prodlouzeni-intervalu-qt-u-pacientu-uzivajicich?highlightwords=citalopram, vyhledáno 28. 9. 2017. 18 Kuryshev, Y. Brown, A. Wang, L., et al.: Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther, 2000, s. 614 620. Fixní kombinace perindopril argininu s amlodipinem prof. MUDr. Jiří Widimský, CSc. Jr. III. interní klinika Centrum pro hypertenzi VFN a 1. LF UK, Praha 1 Todd, P. A. Fitton, A.: Perindopril. A review of its pharmacological pro perties and therapeutic use in cardiovascular disorders. Drugs, 1991, 42, s. 90 114. 2 Grundmann, M.: Perindopril arginin nová sůl inhibitoru ACE perindoprilu. Farmakoterapie, 2007, 3, s. 308 312. 3 Abernethy, D. R.: The pharmacokinetic profile of amlodipine. Am Heart J, 1989, 118, s. 1100 1103. 4 Widimský, J. jr. Cífková, R. Špinar, J., et al.: Doporučení diagnostických a léčebných postupů arteriální hypertenze verze 2007. Doporučení České společnosti pro hypertenzi. Cor et Vasa, 2008, 1, s. K3 23. 5 Brugts, J. J., et al.: The consistency of the treatment effect of an angiotensin-converting enzyme-inhibitor-based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials comparing perindopril indapamide vs. placebo. Eur Heart J, 2009, 30, s. 1385 1394. 6 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. Guidelines Committee. J Hypertens, 2007, 25, s. 1105 1187. 7 Remuzzi, G. Macia, M. Ruggenenti, P.: Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol, 2006, 17, suppl. 2, s. S90 S97.
8 Yusuf, S. Sleight, P. Pogue, J., et al.; for The Heart Outcomes Prevention Evaluation study investigators: Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med, 2000, 342, s. 145 153. 9 The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, s. 782 788. 10 Bertrand, M. E.; on behalf of the EUROPA Executive Committee: Synergistic effect of perindopril and calcium channel blockers in prevention of cardiac events and death in coronary artery disease patients analysis from the EUROPA study. Abstrakt /přednáška, Evropský kardiologický kongres, Mnichov, 2008. 11 Poulter, N. R.; for the ASCOT investigators: Role of blood pressure and other variables in the differential cardiovascular event rate noted in the the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 2005, 366, s. 907 913. 12 The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators: Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Circulation, 2006, 113, s. 1213 1225. 13 Wald, D. S. Law, M. Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med, 2009, 122, s. 290 300. 14 Bahl, V. K. Jadhav, U. M. Thacker, H. P.: Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practise. Results from the STRONG Prospective, Observational, Multicenter study. Am J Cardiovasc Drugs, 2009, 9, s. 135 142. 15 Ferrari, R.: Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin, 2008, 24, s. 3543 3557. 16 Jamerson, K. Weber, M. A. Bakris, G. L., et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patiens. N Engl J Med, 2008, 359, s. 2417 2428. 17 Fox, K., ústní prezentace, Evropský kardiologický kongres, Mnichov 2008. Inhibice systému RAAS perindoprilem ve vztahu k dysfunkci endotelu: studie PERTINENT 1 Fox, K. M.: The European Trial on Reduction of Cardiac Events with Perindoril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovasacular events among patients with stable coronary artery disease: randomised, double-blind, placebo- -controlled multicentre trial (EUROPA). Lancet, 2003, 362, s. 782 788. 2 Braunwald, E. Domanski, M. J. Fowler, S. E., et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med, 2004, 351, s. 2058 2068. 3 Khalil, M. E. Basher, A. W. Brown, E. J. Jr., et al.: A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol, 2001, 37, s. 1757 1764. 4 Remme, W. J. Deckers, J. W. Fox, K. M., et al. for the Europa Investigators: Secondary prevention of coronary disease with ACE inhibition does blood pressure reduction with perindopril explain the benefits in Europa? Cardiovasc Drugs Ther, 2009, 23, s. 161 170. 5 Ceconi, C. Fox, K. M. Remme, W. J., et al.: ACE inhibition with perin dopril and endothelial function. Results of a substudy of the Europa study: PERTINENT. Cardiovasc Res, 2007, 73, s. 237 246. 6 Ferrari, R. Fox, K.: Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate EUROPA story. Drugs, 2009, 69, s. 265 277. Fixní kombinace candesartanu s amlodipinem 1 Le, M. T. Pugsley, M. K. Vauquelin, G., et al.: Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol, 2007, 151, s. 952 962. 2 Matsumori, A. Ono, K. Nishio, R., et al.: Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine, 2000, 12, s. 294 297. 3 Matsumori, A. Nishio, R. Nose, Y.: Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ J, 2010, 74, s. 567 571. 4 Dogrul, A. Yesilyurt, O. Deniz, G., et al.: Analgesic effects of amlodipine and its interaction with morphine and ketorolac-induced analgesia. Gen Pharmacol, 1997, 29, s. 839 845. 5 Ahrens, K. Bramlage, P.: Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension. Drugs Today, 2010, 46, s. 339 350. 6 Takai, S. Jin, D. Shimosato, T., et al.: Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. Hypertens Res, 2011, 34, s. 245 252. 7 Rakugi, H. Ogihara, T. Miyata, Y., et al.: Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 2012, 34, s. 838 848. 8 Yasuno, S. Fujimoto, A. Nakagawa, Y., et al.: Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther, 2012, 10, s. 577 583. 9 Maeda, A. Tamura, K. Kanaoka, T., et al.: Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY). Clin Exp Hypertens, 2012, 34, s. 249 257. 10 Yamaguchi, J. Hagiwara, N. Ogawa, H., et al.: Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study). Am J Cardiol, 2010, 106, s. 819 824. 11 Koyanagi, R. Hagiwara, N. Yamaguchi, J., et al.: Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. J Cardiol, 2013, 62, s. 217 223. 12 Furuhashi, M. Mita, T. Moniwa, N., et al.: Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens Res, 2015, 38, s. 252 259. 13 Sohn, I. S. Kim, C. J. Ahn, T., et al.: Efficacy and tolerability of combination therapy versus monotherapy with candesartan and/ or amlodipine for dose finding in essential hypertension: a phase II multicenter, randomized, double-blind clinical trial. Clin Ther, 2017, 39, s. 1628 1638. XXIV. kongres České internistické společnosti ČLS J. E. Purkyně, 29. 10. 1. 11. 2017 Intervence kardiovaskulárního rizika, proč vítězíme a selháváme 1 veterans administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension results in patients with diastolic blood pressures averaging 115 through 129 mmhg. JAMA, 1967, 202, s. 1028 1034. 2 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 1991, 265, s. 3255 3264. 3 Beckett, N. S. Peters, R. Fletcher, A. E., et al.; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N Engl J Med, 2008, 358, s. 1887 9188. 4 Williamson, J. D. Supiano, M. A. Applegate, W. B., et al.; SPRINT Research Group: Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 75 years: a randomized clinical trial. JAMA, 2016, 315, s. 2673 2682. 5 Ettehad, D. Emdin, C. A. Kiran, A., et al.: Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, 2016, 387, s. 957 967. 6 Franklin, S. S. O Brien. E. Thijs, L., et al.: Masked hypertension: a phenomenon of measurement. Hypertension, 2015, 65, s. 16 20. 7 Bahiru, E. de Cates, A. N. Farr, M. R., et al.: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev, 2017, 3, CD009868. 8 Cífková, R. Skodová, Z. Bruthans, J., et al.: Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens, 2010, 28, s. 2196 2203. 9 Mazzaglia, G. Ambrosioni, E. Alacqua, M., et al.: Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation, 2009, 120, s. 1598 1605. 10 Böhm, M. Schumacher, H. Laufs, U., et al.: Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J, 2013, 166, s. 306 314. 11 Itoh, H.: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study. Prezentpváno na 2017 ESC Congress, Barcelona. 12 Hradec, J. Bultas, J. Kmínek, A., et al.: Jak se léčí statiny v České republice? Cor Vasa, 2011, 53, s. 527 534. 13 Khan, I.: Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor? Prezentováno na 2016 ESC Congress, Řím, poster 4990. 14 Chhatriwalla, A. K. Nicholls, S. J. Wang, T. H., et al.: Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol, 2009, 53, s. 1110 1115. 15 Bertrand, M. Mourad, J. J.: Combining perindopril with a calcium channel blocker and a lipid lowering agent significantly decreases mortality: a subgroup analysis of EUROPA. Circulation, 2013, 128, supl., abstrakt A18906. 16 Chapman, R. H. Benner, J. S. Petrilla, A. A., et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med, 2005, 165, s. 1147 1152. 17 Kotseva, K. De Bacquer, D. De Backer, G., et al.; on behalf of The Euroaspire Investigators. Lifestyle and risk factor management
in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol, 2016, 23, s. 2007 2018. 18 van Halewijn, G. Deckers, J. Tay, H. Y., et al.: Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol, 2017, 232, s. 294 303. 19 Staessen, J. A. Li, Y. Thijs, L., et al.: Blood pressure reduction and cardiovascular prevention: an update including the 2003 2004 secondary prevention trials. Hypertens Res, 2005, 28, s. 385 407. 20 Wald, D. S. Law, M. Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med, 2009, 122, s. 290 300. 21 Sever, P. Dahlöf, B. Poulter, N., et al.; ASCOT Steering Committee Members: Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.Eur Heart J, 2006, 27, s. 2982 2988. 22 Morris, L. S. Schulz, R. M.: Patient compliance an overview. J Clin Pharm Ther, 1992, 17, s. 283 295. 23 Lázaro, P. Murga, N. Aguilar, D., et al.; INERTIA Study Investigators: Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study. Rev Esp Cardiol, 2010, 63, s. 1428 1437. Perindopril erbumin prověřen klinickými studiemi 1 Song, J. C. White, C. M.: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002, 41, s. 207 224. 2 Harder, S. Thurmann, P. A. Ungethum, W.: Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol, 1998, 45, s. 377 380. 3 Alfakih, K. Hall, A. S.: Perindopril. Expert Opin Pharmacother, 2006, 7, s. 63 71. 4 Telejko, E.: Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin, 2007, 23, s. 953 960. 5 Dietz, R. Feilner, K. Gerst, F., et al.: Drug stability testing. Classification of countries according to climatic zone. Drugs made in Germany, 1993, 36, s. 99 103. Porovnání klinického efektu Warfarinu PMCS vůči Warfarinu Orion MUDr. Petr Magrot OKB Lab, a. s., Ústí nad Labem Leona Hrdličková, DiS. SVZŠ, Ústí nad Labem 1 Gao, D. Maurin, M. B.: Physical chemical stability of warfarin so dium. AAPS Pharmasci, 2001, 3, s. 1 8. 2 Souhrn údajů o přípravku Warfarin PMCS 2 mg, Warfarin PMCS 5 mg tablety, sp. zn. sukls 218737/2016. 3 Souhrn údajů o přípravku Warfarin Orion 3 mg, Warfarin Orion 5 mg tablety, sp. zn. sukls 221027/2016. 4 Pecka, M.: Laboratorní hematologie v přehledu, Fyziologie a patofyziologie hemostázy. Český Těšín, Finidr, 2004, s. 214 216. Léčba bolesti v těhotenství s ohledem na změnu farmakokinetiky těhotných PharmDr. Eliška Vaculíková Nemocniční lékárna, Pracoviště klinického farmaceuta Nemocnice s poliklinikou Havířov Mgr. Olga Svobodová Oddělení klinické farmacie Lékárna, FN Ostrava, Farmakologický ústav, LF MU, Brno MUDr. Jan Malaník Gynekologicko-porodní oddělení Slezské nemocnice Opava 1 Schaefer, Ch. Peters, P. Miller, R, K.: Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. Elsevier, 2015, s. 11. 2 International Association for the Study of Pain, online. Dostupné z: http://www.iasp-pain.org/taxonomy, vyhledáno 5. 11. 2015. 3 Medical Dictionary for the Health Professions and Nursing. Dostupné z: http://medical-dictionary.thefreedictionary.com/pain+threshold, vyhledáno 5. 11. 2015. 4 Loebstein, R. Lalkin, A. Koren, G.: Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet, 1997, 33, s. 328 343. 5 Biernetová Vašků, J.: Patofyziologie fetoplacentární jednotky [prezentace PowerPoint]. Brno, projekt: CZ.1.07/2.2.00/28.0041. Dostupné z https://is.muni.cz/el/1411/jaro2014/bvpf0422c/um/nt-patofyziologie_fetoplacentarni_jednotky.pdf, vyhledáno 5. 9. 2017. 6 Kirchneová, M. Suchánková, H. Mrozek, Z.: Anestezie u operací v těhotenství. Klinická farmakologie a farmacie, 2014, 28, s. 62 64. 7 Constantine, M. M.: Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol, 2014, 5, s. 65. 8 Davison, J. M. Dunlop, W.: Changes in renal hemodynamics and tubular function induced by normal human pregnancy. Semin Nephrol, 1984, 4, s. 198. 9 Pacheco, L. Costantine, M. M. Hankins, G. D. V.: Physiologic changes during pregnancy. In: Mattison D. R. (ed.): Clinical Pharmacology During Pregnancy. San Diego, Academic Press, 2013, s. 5 14. 10 Barron, W. M. Lindheimer, M. D.: Renal sodium and water handling in pregnancy. Obstet Gynecol Annu, 1984, 13, s. 35 69. 11 Rubler, S. Damani, P. M. Pinto, E. R.: Cardiac size and performance during pregnancy estimated with echocardiography. Am J Cadiol, 1977, 40, s. 534 540. 12 Clark, S. L. Cotton, D. B. Lee, W., et al.: Central hemodynamic ases sment of normal term pregnancy. Am J Obstet Gynecol, 1989, 161, s. 1439 1442. 13 Capeless, E. L. Clapp, J. F.: When do cardiovascular parametres return to their preconception values? Am J Obstet Gynecol, 1991, 165, s. 883 886. 14 Robson, S. C. Hunter, S. Boys, R. J., et al.: Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol, 1989, 256, s. 1060 1065. 15 Hytten, F. E. Paintin, D. B.: Increase in plasma volume during normal pregnancy. J Obstet Gynaecol Br Emp, 1963, 70, s. 402 407. 16 Taylor, M.: An experimental study of the influence of the endocrine system on the nasal respiratory mucosa. J Laryngol Otol, 1961, 75, s. 972 977. 17 Patofyziologie výměny dýchacích plynů v plicích. Patofyziologie řízení dýchání. Dostupné z: www.med.muni.cz/patfyz/powerpnt/0607/ dych_systpp2006.ppt, prezentace, 18. 10. 2006, vyhledáno 31. 1. 2017. 18 Elkus, R. Popovich, J. Jr.: Respiratory physiology in pregnancy. Clin Chest Med, 1992, 13, s. 555 565. 19 Tsai, C. H. de Leeuw, N. K.: Changes in 2,3-diphosphoglycerate during pregnancy and puerperium in normal women and in beta- -thalassemia heterozygous women. Am J Obstet Gynecol, 1982, 142, s. 520 523. 20 Cappel, M. S. Garcia, A.: Gastric and duodenal ulcers during pregnancy. Gastroenterol Clin North Am, 1998, 27, s. 169 195. 21 Parry, E. Shields, R. Turnbull, A. C.: Transit time in the small intestine in pregnancy. J Obstet Gynaecol Br Commonw, 1970, 77, s. 900 901. 22 Dawes, M. Chowienczyk, P. J.: Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol, 2001, 15, s. 819 826. 23 Clements, J. A. Heading, R. C. Nimmo, W. S., et al.: Kinetics of acetamiophen absorption and gastric emptying in man. Clin Pharmacol Ther, 1978, 24, s. 420 431. 24 Little, B. B.: Pharmacokinetics during pregnancy: evidence-base maternal dose formulation. Obstet Gynecol, 1999, 93, s. 858 868. 25 de Hann, G. J. Edelbroek, P. Segers, J., et al.: Gestation-induced changes in lamotrigine pharmacokinetics: a monitherapy study. Neurology, 2004, 63, s. 571 573. 26 Paralen 500. SÚKL, 2010, dostupné z: http://www.sukl.cz/modules/ medication/detail.php?code=0155148&tab=texts, vyhledáno 10. 8. 2017. 27 Roberts, I. Robinson, M. J. Mughal, M. Z., et al.: Paracetamol metabolites in the neonate following maternal overdose. Br J Clin Pharmacol, 1984, 18, s. 201 206. 28 Nosková, P.: Léčba bolesti během gravidity a laktace. Medicína pro praxi, 2011, 8, s. 370 373. 29 Novalgin. SÚKL, 2010, dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0055823&tab=texts, vyhledáno 10. 8. 2017. 30 Fitzpatrick, F. A.: Cyclooxygenase enzymes: regulation and function. Curr Pharm Des, 2004, 10, s. 577 588. 31 Werler, M. M. Mitchlel, C. A. Honein, M. A.: Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? National Bitrh Deffects Prevention Study. Am J Med Genetics, 2009, 149A, s. 1399 1406. 32 Gastroschisis. Velký lékařský slovník, Maxdorf, 1998 2017, dostupné z: http://lekarske.slovniky.cz/lexikon-pojem/gastroschisis, vyhledáno 10. 3. 2017. 33 Østensen, M. Förger, F.: Management of RA medications in pregnant patients. Nat Rev Rheumatol, 2009, 5, s. 382 390. 34 Celebrex. SÚKL, 2010, dostupné z: http://www.sukl.cz/modules/medication/detail.php?kod=0085026, vyhledáno 25. 8. 2017. 35 Arcoxia. SÚKL, 2010, dostupné z: http://www.sukl.cz/modules/medication/detail.php?kod=0099969, vyhledáno 25. 8. 2017. 36 Kassim, Z. Greenough, A.: Neonatal abstinence syndrom: Identification and management. Current Pediatrics, 2006, 16, s. 172 175. 37 Claahsen-van der Grinten, H. L. Verbruggen, I. van den Berg, P. P., et al.: Different pharmacokinetics of tramadol in mother treated for labour pain and in their neonates. Eur J Clin Pharmacol, 2005, 61, s. 523 529. 38 Reiff Eldridge, R. Heffner, C. R. Ephross, S. A., et al.: Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol, 2000, 182, s. 159 163.
Tapentadol v léčbě chronické nenádorové bolesti kazuistika MUDr. Lenka Klimešová ARIM, Nemocnice Milosrdných bratří, Brno 1 Baron, R. Likar, R. Martin-Mola, E., et al.: Effectiveness of tapentadol prolonged release compared with oxycodone/naloxone for management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 study. Pain Practice, 2016,16, s. 580 599. 2 Baron, R. Jansen, J.-P. Binder, A., et al.: Tolerability, safety, and quality of life with tapentadol prolonged release compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Practice, 2016, 16, s. 600 619. 3 Buynak, R. Shapiro, D. Y. Okamoto, A., et al.: Efficacy and safety of tapentadol extended release for the management of chronic low back pain:results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother, 2010, 11, s. 1787 1804. 4 Nicholson, B.: Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract, 2009, 9, s. 71 81. 5 Freynhagen, R. Baron, R. Gockel, U., et al.: paindetect: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin, 2006, 22, s. 1911 1920. 6 Lange, B. Kuperwasser, B. Okamoto, A., et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther, 2010, 27, s. 381 399. 7 Sánchez del Águila, M. J. Schenk, M. Kern K.-U. Drost, T., et al.: Practical considerations for the use of tapentadol prolonged release for management of severe chronic pain. Clin Ther, 2015, 7, s. 94 113. 8 Schwartz, S. Etropolski, M. Shapiro, D. Y., et al.: Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin, 2011, 27, s. 151 162. Nová možnost léčby revmatoidní artritidy Olumiant MUDr. Olga Růžičková Revmatologický ústav, Praha 1 Genovese, M. C., et al.: Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med, 2016, 374, s. 1243 1252. 2 Fleischman, R., et al.: Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease- -modifying antirheumatic drug treatment. Arthritis Rheumatol, 2017, 69, 3, s. 506 517. 3 Dougados, M. van der Heijde, D. Chen, Y-C., et al.: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis, 2017, 76, s. 88 95. 4 Van der Heijde, D. Dougados, M. Chen, Y-C., et al.: THU0168 baricitinib inhibits radigraphic progression of structural joint demage at 1 year in patients with rheumatoid arthritis (RA) and an inadequqte response to csdmards. Ann Rheum Dis, 2016, 75, s. 244 245. 5 Taylor, P. C. Keystone, E. C. van der Heijde, D., et al.: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med, 2017, 376, s. 652 662. 6 Závada, J.: Komentář ke studii. Farmakoterapie, 2017, 3, s. 440 442. 7 Šenolt, L. Mann, H. Závada, J., et al.: Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy. Čes Revmatol, 2017, 25, s. 8 24. 8 Schwartz, D., et al.: Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol, 2016, 12, s. 25 36. 9 Norman, P.: Selective JAK inhibitors in development for rheumatoid arthritis Expert Opin Investig Drugs, 2014, 23, s. 1067 1073. Secukinumab v léčbě pacientky se závažným průběhem psoriázy a psoriatické artritidy kazuistika MUDr. Martina Kojanová, Ph.D. MUDr. Jorga Fialová Dermatovenerologická klinika 1. LF UK a VFN, Praha MUDr. Liliana Šedová Revmatologický ústav, Praha, Revmatologická klinika 1. LF UK, Praha 1 Kojanová, M. Fialová, J. Cetkovská, P., et al.: Analýza pacientů se středně těžkou až těžkou psoriázou před zahájením biologické léčby v České republice údaje z registru BIOREP 2005 2016. Čs Derm, 2016, 5, s. 223 232. 2 Dostupné z: http://www.sukl.cz/modules/medication/search.php, 3 Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0167600&tab=prices, 4 Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0210317&tab=prices, 5 Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0209310&tab=prices, 6 Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code=0210310&tab=prices, 7 Dostupné z: http://www.revmatologicka-spolecnost.cz/doporucene- -postupy-crs, 8 Costa, L. Perricone, C. Chimenti, M. S., et al.: Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D, 2017, 4, s. 509 522. 9 Merola, J. F. Lockshin, B. Mody, E. A.: Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum, 2017, 1, s. 29 37. 10 Abrouk, M. Gandy, J. Nakamura, M., et al.: Secukinumab in the treatment of psoriasis and psoriatic arthritis: a review of the literature. Skin Therapy Lett, 2017, 4, s. 1 6. 11 McInnes, I. B. Mease, P. J. Kirkham, B., et al.: Secukinumab, a human anti-interleukin-17a monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo- -controlled, phase 3 trial. Lancet, 2015, 9999, s. 1137 1146. 12 Behrens, F. Cañete, J. D. Olivieri, I., et al.: Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford), 2015, 5, s. 915 926. 13 Kerdel, F. Zaiac, M.: An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther, 2015, 6, s. 390 403. 14 Mrowietz, U. de Jong, E. M. Kragballe, K., et al.: A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol, 2014, 28, s. 438 453. 15 Ormerod, A. D.: Switching biologics for psoriasis. Br J Dermatol, 2010, 163, s. 667 669. 16 Brezinski, E. A. Armstrong, A. W.: Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. Semin Cutan Med Surg, 2014, 33, s. 91 97. 17 Strober, B. E. Bissonnette, R. Fiorentino, D., et al.: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol, 2016, 5, s. 851 861. 18 Yamauchi, P. S. Bissonnette, R. Teixeira, H. D., et al.: Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-tnf agent. J Am Acad Dermatol, 2016, 3, s. 612 618. 19 Menter, A. Papp, K. A. Gooderham, M., et al.: Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol, 2016, 7, s. 1148 1158. 20 Gniadecki, R. Bang, B. Bryld, L. E., et al.: Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol, 2015, 172, s. 244 252. 21 Griffiths, C. E. Strober, B. E. van de Kerkhof, P., et al.: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med, 2010, 362, s. 118 128. 22 Blauvelt, A. Reich, K. Tsai, T. F., et al.: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol, 2017, 1, s. 60 69. 23 Thaçi, D. Blauvelt, A. Reich, K., et al.: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol, 2015, 3, s. 400 409. 24 Pelechas, E. Memi, T. Voulgari, P. V., et al.: A case of recalcitrant psoriatic arthritis to TNF inhibitors improved after administration of secukinumab, an IL-17A inhibitor. Rheumatol Ther, 2017, 2, s. 509 513. Fixní kombinace azelastinu a fluticason propionátu lékový profil MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha 1 Bousquet, J. Bachert, C. Bernstein, J., et al.: Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother, 2015, 16, s. 913 928. 2 Derendorf, H. Munzel, U. Petzold, U., et al.: Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol, 2012, 74, s. 125 133.